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Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous 
coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT 
registry was obtained by merging two registries on coronary bifurcations. Three groups were 
compared in a two-by-two fashion: short-term DAPT ( 6 months), intermediate-term DAPT 
(6-12 months) and extended DAPT (>12 months). Major adverse cardiac events (MACE) (a 
composite of all-cause death, myocardial infarction (MI), target-lesion revascularization and 
stent thrombosis) were the primary endpoint. Single components of MACE were the 
secondary endpoints. Events were appraised according to the clinical presentation: chronic 
coronary syndrome (CCS) vs acute coronary syndrome (ACS).  5537 patients (3231 ACS, 
2306 CCS) were included. After a median follow-up of 2.1 years (IQR 0.9-2.2), extended 
DAPT was associated with a lower incidence of MACE compared with intermediate-term 
DAPT (2.8% vs 3.4%, adjusted HR 0.23 [0.1-0.54], p<0.001), driven by a reduction of all-
cause death in the ACS cohort. In the CCS cohort, an extended DAPT strategy was not 
associated with a reduced risk of MACE. In conclusion, among real-world patients receiving 
PCI for coronary bifurcation, an extended DAPT strategy was associated with a reduction of 
MACE in ACS but not in CCS patients.  









Coronary bifurcation stenosis account for 15-20% of lesions treated with percutaneous 
coronary intervention (PCI)1. Despite PCI is currently a routine practice in this setting2, it has 
been historically characterized by a lower procedural success rate and worse clinical 
outcomes as compared with stenting of noncomplex coronary lesions3. The most suitable 
dual antiplatelet therapy (DAPT) strategy in this context, in which suboptimal procedural 
results (i.e. malapposed stent struts, inadequate stent expansion, excessive metal 
scaffolding) are often observed, is yet to be determined. Latest years’ research focused on 
the optimal intensity and duration of antiplatelet treatments following PCI with discordant 
findings4-5, mostly suggesting that the benefit of an extended DAPT strategy is modulated 
by the individual thrombotic risk and by clinical presentation. Yet, patients with high-risk 
anatomical features such as coronary bifurcation lesions or unprotected left main (ULM) 
involvement were mostly underrepresented or excluded in these trials, thus limiting the 
inferential aim of these findings in the context of complex coronary disease. Consequently, 
we explored the impact of different DAPT duration strategy in a large cohort of patients 
treated with PCI with DES for coronary bifurcation lesions across different clinical 
presentations. 
METHODS. 
Two large datasets (COBIS III, NCT01642992 and RAIN, NCT03544294) of patients treated 
with PCI for coronary bifurcations were merged in prespecified forms to create the 
BIFURCAT (comBined Insights From the Unified RAIN and COBIS bifurcAtion regisTries) 
registry, encompassing 5537 patients. Details about both registries are reported in the 
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supplementary appendix. Patients were classified in groups based on DAPT duration after 
PCI and to evaluate prognosis from landmark time-points. We identified three groups of 
interest: 
Short-term DAPT: patients with a DAPT duration ≤ six months 
Intermediate-term DAPT: patients with a DAPT duration > six months and  
Extended DAPT: patients with a DAPT duration > 12 months 
The groups were compared in a two-by-two fashion. For each comparison only the events 
occurring after the shortest landmark time-point of DAPT withdrawal after PCI were 
accounted for. For instance, to compare outcomes of intermediate-term DAPT vs short-term 
DAPT, only events occurring after 6 months were considered. Likewise, to compare 
extended-term DAPT vs intermediate-term DAPT we only included events occurring after 
12 months. Details about PCI, pharmacologic therapy and data collection are reported in 
the supplementary appendix (see supplementary methods). Major adverse cardiac events 
[(MACE), defined as a composite of all-cause death, myocardial infarction (MI), target-lesion 
revascularization (TLR) and definite or probable stent thrombosis (ST)] were the primary 
endpoint. Single outcomes constituting the composite of MACE were the secondary 
endpoints. All clinical events were classified based on the recommendations from the 
Academic Research Consortium (ARC)6. Endpoints of interest were appraised according to 
the clinical presentation (ACS vs chronic coronary syndrome, CCS). Subgroup analyses 
according to the presence of disease involving distal ULM, DAPT score7 and stenting 
technique (provisional vs 2 stents) were also performed.  Categorical variables are reported 
as count and percentages. Continuous variables as mean and standard deviations or 
interquartile range (IQR). Parametric (T-test) and non-parametric (Mann-Whitney test) tests 
were used to assess differences between continuous variables, while chi-square test was 
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used for categorical variables. Adjustement was performed with Cox multivariate analysis 
and inverse probability of treatment weighting (IPTW). For Cox multivariate analysis, 
variables with significant differences at univariate analysis (p<0.05) or clinically relevant 
were included in the multivariable model, along with the referral registry (COBIS vs. RAIN) 
and the year of enrolment (meant as before and after 2015). Adjusted survival analysis with 
Cox adjustment was performed for MACE. For IPTW, the following steps were performed: 
(a) variables with >10% missing values were excluded from the merged study dataset; (b) 
multiple imputation was carried with polytomous logistic regression, logistic regression using 
the R mice package (version 3.8.0), leading to five imputed different datasets; (c) matching 
and weighting of the multiple imputed datasets were performed using the R MatchThem 
package (version 0.9.3), (d) Rubin’s rule was used to get pooled propensity score-adjusted 
hazard ratio (HR) estimates for each endpoint according to this method. A formal sample 
size calculation is reported in the appendix. The a priori statistical significance level was set 
at α = 0.05. Statistical analyses were conducted using R Statistical Software version 3.6.3 
(R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 24.0, SPSS 
Inc., Chicago, Illinois, US). 
RESULTS 
A total of 5537 patients were included in the final population (Figure 1): 3231 (58%) 
presenting with ACS and 2306 (42%) with CCS. The median follow-up was 2.1 years (IQR 
0.9-2.2). 204 patients (3.8%) were lost at follow up and therefore not considered for the 
outcome analysis. Most of the patients enrolled before 2015 were treated with extended 
DAPT, whereas starting from 2015 onwards the majority both in ACS and CCS subgroup 
received intermediate-term DAPT, (Appendix Tables 1 and 2). In the ACS cohort, 238 (7%) 
patients received short-term DAPT (median length of DAPT 3 months, IQR 1-4), 1536 (48%) 
intermediate-term DAPT (12 months, IQR 12-12) and 1457 (45%) extended DAPT (24 
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months, IQR 23-24). In the CCS cohort, 144 (6%) patients received short-term DAPT 
(median length 1 month, IQR 1-3), 1208 (52%), intermediate-term DAPT (12 months, IQR 
12-12) and 954 (42%) extended DAPT (24 months, IQR 23-24). Baseline clinical features 
are reported in Table 1. Procedural features are outlined in Supplementary Table 3.   
Among ACS patients, extended DAPT was associated with a lower incidence of MACE as 
compared with intermediate-term DAPT (2.8% vs. 3.4%, adjusted HR 0.23, 95% CI 0.11-
0.54, p<0.001 and adjusted HR 0.27, 95% CI 0.18-0.43, p 0.04, with Cox multivariate 
analysis and with IPTW, respectively). No significant differences were observed in the 
incidence of MACE when comparing the intermediate-term DAPT group with the short-term 
DAPT group (5.3 % vs 8%, HR 0.45, 95% CI 0.29-1.32, p 0.17 and HR 0.67 95% CI 0.33-
1.34, p = 0.26 after Cox multivariate adjustment and IPTW, respectively), Table 2 and 
Figure 2.  For CCS patients, extended DAPT and intermediate DAPT regimens were not 
associated with a reduced risk of MACE after multivariate as well as IPTW adjustment 
(Table 2 and Figure 2).  Among ACS patients, extended DAPT compared with intermediate-
term DAPT was associated with a reduced risk of all-cause death after Cox multivariate 
adjustment (1.4% vs. 1.6%, HR 0.16, 95% CI 0.04-0.9, p 0.04) but not at IPTW analysis (HR 
0.86, 95% CI 0.64-1.73, p 0.71), Table 2. No differences were observed between the 
intermediate and the short-term DAPT groups.  For CCS patients, a similar adjusted risk of 
all-cause death was observed among the three subgroups when compared in a two-by-two 
fashion, Table 2. A lower unadjusted incidence of MI (0.6% vs 0.9%), TLR (0.9% vs 1.4%) 
and ST (0.1% vs 0.3%) was observed among ACS patients treated with an extended DAPT 
strategy as compared with those treated with DAPT for 6-12 months, Table 2. However, 
such differences were not significant after IPTW adjustment. Among CCS patients, a lower 
incidence of ST was observed with longer DAPT regimens (0.5% vs 1.4% for intermediate 
DAPT vs short-DAPT and 0% vs 0.4% for extended DAPT vs intermediate DAPT), with a 
significant difference for patients treated for 6-12 months as compared to those on DAPT 
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for  6 months after IPTW adjustment (HR 0.14 95%CI 0.03-0.74, p=0.02), but not with Cox 
multivariate analysis (HR 0.45, 95% CI 0.04-4.34, p=0.66). The risk of MI and TLR according 
to DAPT duration subgroups within the CCS cohort was not significantly different. 
In the ACS cohort, extended DAPT reduced the risk of MACE compared with intermediate-
term DAPT for all the subgroups explored (ULM vs non-ULM, stenting strategy and DAPT 
score < or  2). Intermediate-term DAPT compared to short-term DAPT reduced the risk of 
MACE only for patients with DAPT score  2 (HR 0.36, 95% CI 0.13-0.99, p 0.04), while 
there were no differences in the other subgroups analyzed (Figure 3, panel A and Appendix 
Table 4). In the CCS cohort, no differences in MACE incidence according to DAPT duration 
were observed across all the explored subgroups (Figure 3, panel B and Appendix Table 4). 
DISCUSSION 
The main findings of this study, investigating the issue of the optimal DAPT duration in 
patients treated with PCI for coronary bifurcation according to clinical presentation can be 
resumed as follows: ACS patients undergoing PCI for coronary bifurcation lesions who 
received an extended (>12 months) DAPT had a lower incidence of MACE compared with 
those treated with an intermediate-term DAPT (6-12 months); the lower incidence of MACE 
in ACS patients receiving DAPT for > 12 months compared to those receiving DAPT for of 
6-12 months was confirmed after multivariate and IPTW adjustment and was consistent 
despite the stenting technique (one vs 2 stents), the site of bifurcation (ULM vs no ULM) and 
the DAPT score. Furthermore, a higher incidence of MACE was observed in patients with a 
DAPT score  2 and a DAPT duration  6 months compared to those treated for 6-12 
months. A similar risk of MACE was instead observed among patients admitted for CCS and 
treated with different DAPT regimens. Such result was confirmed among all the analyzed 
subgroups.   
9 
 
Complex interventional scenarios intuitively represent a driver in favor of a prolonged 
antithrombotic treatment, although actual evidence supporting this approach is scant. The 
current ESC guidelines mostly rely on patients ’ clinical presentation (ACS vs CCS) to 
recommend a diversification in DAPT strategy, with a weak recommendation to consider 
prolonged DAPT duration in patients undergoing complex PCI (class of recommendation 
IIb)8. Such indication relies on a pooled analysis of six RCTs assessing the impact of DAPT 
duration according to PCI complexity (frequently but not always on the basis of a bifurcation 
treatment), where authors found that patients who underwent complex PCI had a two-fold 
increase risk of MACE (5.0% vs. 2.5%; P = 0.001) and that long-term DAPT ( 12 months) 
compared with short-term (3 or 6 months) was associated with a reduction in MACE in this 
group as compared with the noncomplex PCI cohort at a median follow up of 392 days9. Of 
interest, despite a non-significant interaction, the benefit of prolonged DAPT among complex 
PCI groups appeared more relevant in high-risk ACS patients (HR 0.37, 95%CI 0.16-0.83) 
as compared with those admitted for unstable angina (HR 0.75, 95%CI 0.45-1.23), thus 
being overall consistent with our findings.  In a previous analysis from the COBIS registry, 
Jang et al10 found that a prolonged DAPT (>12 months) was associated with a reduction in 
MI and all-cause death as compared to DAPT < 12 months. However, in contrast with such 
work, we found the admission diagnosis to modulate this benefit with only ACS patients 
taking advantage from a long-term antithrombotic treatment. Both patient- (clinical 
presentation and extent of CAD) and procedural-related (PCI complexity) features may 
influence the future thrombotic risk and therefore the overall clinical benefit of an extended 
DAPT regimen. The extended cohort considered in the BIFURCAT registry as compared 
with the solely COBIS population is characterized by a larger use of very-thin strut-stents 
(as per RAIN registry inclusion criteria)11. This difference may have translated in the 
selection of a cohort in whom patients-related factors (rather than stent- and lesion-related 
10 
 
features) had a dominant role in driving the benefit of a prolonged DAPT regimen, thus 
probably accounting for the different findings according to the clinical admission setting. In 
accordance with such hypothesis, we found a significant reduction of MACE in ACS patients 
treated with extended DAPT regardless of the stenting technique (one vs 2 stent) used.  
RCTs in the modern DES era showed that short-term DAPT should be considered as the 
safest strategy, being consistently associated with a significant reduction in bleeding events 
without increase in ischemic events, both in the ACS setting and in unselected cohorts12-14. 
Of note, none of these trials was specifically designed to determine the optimal DAPT 
duration in complex anatomical settings and patients with coronary bifurcations were 
therefore underrepresented (20% and 15% in HOST-REDUCE-ACS and TICO trial, 
respectively). Moreover, in a post-hoc analysis of the TWILIGHT Trial, among 2342 patients 
undergoing complex PCI who completed three months of DAPT, the continuation of 
ticagrelor monotherapy was associated with a lower incidence of bleeding events without 
increasing the risk of ischemic events as compared to continuing DAPT15. However, such 
analysis was not adequately powered for ischemic endpoints and differently from the 
BIFURCAT population patients with STEMI were not included as per study protocol inclusion 
criteria. In our ACS cohort, the reduction of all-cause mortality may suggest that in peculiar 
settings like coronary bifurcation disease, the benefits from reducing ischemic events may 
offset the potential increase in bleeding risk with prolonged DAPT. Such hypothesis should 
be further confirmed in future studies and should be interpreted with caution in the absence 
of data about bleeding events. 
Our results should be interpreted in the context of some limitations. First, this study has an 
observational design. The choice of different DAPT strategies was not based on 
randomization.  Despite IPTW adjustment, a potential bias coming from unmeasured 
variables that would be adequately prevented only through a randomized design cannot be 
excluded. However, to our knowledge no RCT is currently ongoing to address the issue of 
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optimal DAPT duration in the specific setting of coronary bifurcations. Second, data on 
bleeding events were not available. We inferred the net clinical benefit of a prolonged DAPT 
strategy by performing a subgroup analysis according to DAPT score. Despite our findings 
were consistent with the main analysis, the potential harm coming from such strategy could 
not be directly assessed. Due to the observational nature of the study, the groups analyzed 
were not balanced in their size, especially regarding the short-term DAPT group. However, 
this may reflect the contemporary practice and the physicians’ preference for a long-term 
DAPT in this setting.  In conclusion, in this large real-world cohort of patients treated with 
PCI on bifurcation coronary lesions we found that an extended DAPT strategy (>12 months) 
compared with a short- and intermediate-term DAPT (<6 months and 6-12 months, 
respectively) was associated with a reduction of MACE in patients admitted with ACS, 
regardless of DAPT score, distal ULM involvement and stenting technique (provisional vs 
two stents). In patients admitted for CCS, the risk of MACE was not affected by DAPT 
duration, but the risk of all-cause death was significantly lower in the extend-term DAPT 
group compared to the short-term DAPT group. These results suggest that a prolonged 
DAPT strategy may improve long-term clinical outcomes in patients treated with PCI for 
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Table 1: Baseline features of the population. 
Legend: ACS: acute coronary syndrome; CCS: Chronic Coronary Syndrome; eGFR: estimated glomerular filtration rate; PCI: 
percutaneous coronary intervention; CABG: coronary artery bypass graft; MI: myocardial infarction; STEMI: ST-segment elevation 




Table 2: Long term outcomes. 
 
Legend: DAPT: dual antiplatelet therapy; ACS: acute coronary syndrome; CCS: Chronic Coronary Syndrome; MACE: major adverse 
cardiovascular events; MI: myocardial infarction; TLR: target lesion revascularization; ST: stent thrombosis. HR: hazard ratio; CI: 
confidence interval; IPTW: Inverse probability of treatment weighting. 
* adjusted for age, gender, hyperlipidemia, diabetes mellitus, renal disease, distal ULM, provisional versus 2 stents strategy, use of 
imaging, registry (COBIS versus RAIN) kind of DAPT and 2010-2014 versus 2015-2017 





Figure 1: Study Design. DAPT: dual antiplatelet therapy. 
 
Figure 2: Adjusted survival from MACE for DAPT  6 months, DAPT 6-12 months and 
DAPT>12 months (above: acute coronary syndrome; below: chronic coronary syndrome 
cohort). Only significant p values (<0.05) are reported.  For the comparison between DAPT 
≤ 6 months and 6-12 months, time on the x axis starts from 6 months after the index PCI. 
For the comparison between DAPT 6-12 months and DAPT > 12 months, x axis starts from 





Figure 3: Subgroup analysis for MACE. ULM: unprotected left main. DAPT: dual antiplatelet 
therapy 
